Evidence of the principle of similitude in modern fatal iatrogenic events

Homeopathy

Volumn 95, Issue 4, 2006, Pages 229-236

  Teixeira, M Z ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

compensatory response; fatal iatrogenic event; homeostasis; paradoxical reaction; rebound effect; similitude

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANTACID AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANXIOLYTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUTICASONE; HYDRALAZINE; HYPNOTIC SEDATIVE AGENT; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NITRATE; NITROPRUSSIDE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PROSTAGLANDIN A1; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ALLOPATHY; ANGINA PECTORIS; ANXIETY DISORDER; ARTICLE; ASTHMA; BRONCHOSPASM; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DRUG FATALITY; DRUG MEGADOSE; GASTRITIS; GASTRODUODENAL ULCER; HEALTH PRACTITIONER; HEART ARRHYTHMIA; HEART INFARCTION; HOMEOSTASIS; HUMAN; HYPERALGESIA; HYPERTENSION; IATROGENIC DISEASE; INFLAMMATION; INSOMNIA; MANIA; PALLIATIVE THERAPY; PANIC; PARADOXICAL DRUG REACTION; REBOUND; SIDE EFFECT; SODIUM RETENTION; SOMNOLENCE; ST SEGMENT ELEVATION; STOMACH DISEASE; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; THORAX PAIN; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

ANTIDEPRESSIVE AGENTS; ASPIRIN; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PRESCRIPTIONS; EVIDENCE-BASED MEDICINE; HOMEOPATHY; HUMANS; IATROGENIC DISEASE; LACTONES; MATERIA MEDICA; PRESCRIPTIONS, DRUG; RESEARCH DESIGN; SULFONES; TREATMENT OUTCOME;

EID: 33749047860     PISSN: 14754916     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.homp.2006.06.004     Document Type: Article

References (92)

1. Hahnemann S. Organon of Medicine, 6th Edn. (Translated by William Boericke). New Delhi: B Jain Publishers, 1991.
2. Teixeira M.Z. Semelhante cura semelhante: o princípio de cura homeopático fundamentado pela racionalidade médica e científica [Similar cures similar: the homoeopathic cure principle based by the medical and scientific rationality] (1998), Editorial Petrus, São Paulo
3. Teixeira M.Z. Similitude in modern pharmacology. Homeopathy 88 (1999) 112-120
4. Teixeira M.Z. Homeopathic use of modern medicines: utilisation of the curative rebound effect. Med Hypotheses 60 (2003) 276-283
5. Teixeira M.Z. Paradoxical strategy for treating chronic diseases: a therapeutic model used in homeopathy for more than two centuries. Homeopathy 94 (2005) 265-266
6. Ardelt W., Pasold K., and Hillemanns H.G. Side effects of drug for thromboembolism prophylaxis. Results from the University Women's Clinic Freiburg/Br. Fortschr Med 97 (1979) 471-474
7. Terashita Z., Imura Y., Tanabe M., et al. CV-4151-a potent, selective thromboxane A2 synthetase inhibitor. Thromb Res 41 (1986) 223-237
8. Averkov O.V., Zateishchikov D.A., Gratsianskii N.A., Logutov Iu.A., Iavelov I.S., and Ianus V. Unstable angina: effect of aspirin and heparin on treatment outcome in hospital patients (a double-blind, placebo-controlled study). Kardiologiia 33 (1993) 4-9
9. Mousa S.A., Forsythe M.S., Bozarth J.M., and Reilly T.M. Effect of single oral dose of aspirin on human platelet functions and plasma plasminogen activator inhibitor-1. Cardiology 83 (1993) 367-373
10. Beving H., Eksborg S., Malmgren R.S., Nordlander R., Ryden L., and Olsson P. Inter-individual variations of the effect of low dose aspirin regime on platelet cyclooxygenase activity. Thromb Res 74 (1994) 39-51
11. Raskob G.E., Durica S.S., Morrissey J.H., Owen W.L., and Comp P.C. Effect of treatment with low-dose warfarin-aspirin on activated factor VII. Blood 85 (1995) 3034-3039
12. Col J. Current point of view on medical treatment of unstable angina. Arch Mal Coeur Vaiss Spec (5) (1996) 15-18
13. Schulman S.P., Goldschmidt-Clermont P.J., Topol E.J., et al. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation 94 (1996) 2083-2089
14. Aguejouf O., Belougne-Malfati E., Doutremepuich F., Belon P., and Doutremepuich C. Tromboembolic complications several days after a single-dose administration of aspirin. Thromb Res 89 (1998) 123-127
15. Main C., Palmer S., Griffin S., et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol Assess 8 (2004) 1-156
16. Doutremepuich C., Aguejouf O., Pintigny D., Sertillanges M.N., and De Seze O. Thrombogenic properties of ultra-low-dose of acetylsalicylic acid in a vessel model of laser-induced thrombus formation. Thromb Res 76 (1994) 225-229
17. Doutremepuich C.H., Aguejouf O., and Belon P. Effects of ultra-low dose aspirin on embolization in a model of laser-induced thrombus formation. Semin Thromb Hemost 22 Suppl 1 (1996) 67-70
18. Aguejouf O., Malfatti E., Belon P., and Doutremepuich C. Effects of acetyl salicylic acid therapy on an experimental thrombosis induced by laser beam. Thromb Res 99 (2000) 595-602
19. Belougne-Malfatti E., Aguejouf O., Doutremepuich F., Belon P., and Doutremepuich C. Combination of two doses of acetyl salicylic acid: experimental study of arterial thrombosis. Thromb Res 90 (1998) 215-221
20. Doutremepuich C., Aguejouf O., Malfatti E., and Belon P. Time related neutralization of two doses acetyl salicylic acid. Thromb Res 100 (2000) 317-323
21. Doutremepuich C., Pailley D., Anne M.C., De Seze O., Paccalin J., and Quilichini R. Template bleeding time after ingestion of ultra-low doses of acetylsalicylic acid in healthy subjects. Preliminary study. Thromb Res 48 (1987) 501-504
22. Doutremepuich C., De Seze O., Le Roy D., Lalanne M.C., and Anne M.C. Aspirin at very ultra low dosage in healthy volunteers: effects on bleeding time, platelet aggregation and coagulation. Haemostasis 20 (1990) 99-105
23. Lalanne M.C., Doutremepuich C., de Seze O., and Belon P. What is the effect of acetylsalicylic acid at ultra low dose on the interaction platelets/vessel wall?. Thromb Res 60 (1990) 231-236
24. a Annual International Scientific Assembly of The American College of Chest Physicians, Orlando, EUA, 2003. CHEST 124 (2003) 148S
25. Ferrari E., Benhamou M., Cerboni P., and Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 45 (2005) 456-459
26. Aetna InteliHealth, Harvard Medical School. Health News: Aspirin withdrawal may pose risk to coronary patients. Available on: 〈http://www.intelihealth.com/IH/ihtIH/WSAZR000/333/341/371250.html〉.
27. Maulaz A.B., Bezerra D.C., Michel P., and Bogousslavsky J. Effect of discountinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 62 (2005) 1217-1220
28. Andrioli G., Lussignoli S., Ortolani R., Minuz P., Vella F., and Bellavite P. Dual effects of diclofenac on human platelet adhesion in vitro. Blood Coagul Fibrinolysis 7 (1996) 153-156
29. Andrioli G., Lussignoli S., Gaino S., Benoni G., and Bellavite P. Study on paradoxical effects of NSAIDs on platelet activation. Inflammation 21 (1997) 519-530
30. Fischer L.M., Schlienger R.G., Matter C.M., Jick H., and Meier C.R. Discontinuation of nonsteroidal anti-inflammatory drugs is associated with an increased risk of acute myocardial infarction. Arch Intern Med 164 (2004) 2472-2476
31. Sibon I., and Orgogozo J.M. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology 62 (2004) 1187-1189
32. Nelson M.R., Liew D., Bertram M., and Vos T. Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged>or=70. BMJ 330 (2005) 1306
33. Pijak M.R. Rebound inflammation and the risk of ischemic stroke after discontinuation of aspirin therapy. Arch Neurol 63 (2006) 300-301
34. Griffin M.R., Stein C.M., Graham D.J., Daugherty J.R., Arbogast P.G., and Ray W.A. High frequency of use of rofecoxib at greater than recommended doses: cause for concern. Pharmacoepidemiol Drug Saf 13 (2004) 339-343
35. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
36. Graham D.J., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 (2005) 475-481
37. Hippisley-Cox J., and Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330 (2005) 1366
38. Ray W.A., Stein C.M., Daugherty J.R., Hall K., Arbogast P.G., and Griffin M.R. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360 (2002) 1071-1073
39. Johnsen S.P., Larsson H., Tarone R.E., et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 165 (2005) 978-984
40. Levesque L.E., Brophy J.M., and Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 142 (2005) 481-489
41. Levesque L.E., Brophy J.M., and Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ 174 (2006) 1563-1569
42. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., and Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332 (2006) 1302-1308
43. Jureidini J.N., Doecke C.J., Mansfield P.R., Haby M.M., Menkes D.B., and Tonkin A.L. Efficacy and safety of antidepressants for children and adolescents. BMJ 328 (2004) 879-883
44. Culpepper L., Davidson J.R., Dietrich A.J., Goodman W.K., Kroenke K., and Schwenk T.L. Suicidality as a possible side effect of antidepressant treatment. J Clin Psychiatry 65 (2004) 742-749
45. Jick H., Kaye J.A., and Jick S.S. Antidepressants and the risk of suicidal behaviors. JAMA 292 (2004) 338-343
46. Leon A.C., Marzuk P.M., Tardiff K., and Teres J.J. Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. J Clin Psychiatry 65 (2004) 915-918
47. Gunnell D., and Ashby D. Antidepressants and suicide: what is the balance of benefit and harm. BMJ 329 (2004) 34-38
48. Lenzer J. Secret US report surfaces on antidepressants in children. BMJ 329 (2004) 307
49. Nelson R. Antidepressant use in children-safe or not? Hiding unfavorable data makes it hard to know. Am J Nurs 104 (2004) 25-26
50. US Food and Drug Administration. FDA Public Health Advisory (October 15, 2004): "Suicidality in children and adolescents being treated with antidepressant medications". Available on: 〈http://www.fda.gov/cder/drug/antidepressants/SSRIPHA200410.htm〉.
51. US Food and Drug Administration. FDA Public Health Advisory (June 30, 2005): 'Suicidality in adults being treated with antidepressant Medications'. Available on: 〈http://www.fda.gov/cder/drug/advisory/SSRI200507.htm〉.
52. Aetna InteliHealth, Harvard Medical School. Health News: FDA warns of suicide risk for Paxil. Available on: 〈http://www.intelihealth.com/IH/ihtIH/EMIHC000/333/8014/466054.html〉.
53. Spencer T.J., Biederman J., Wilens T.E., and Faraone S.V. Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry 63 Suppl 12 (2002) 16-22
54. Hesse L.M., Von Moltke L.L., and Greenblatt D.J. Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 17 (2003) 513-532
55. Wichniak A., Brunner H., Ising M., Pedrosa Gil F., Holsboer F., and Friess E. Impaired hypothalamic-pituitary-adrenocortical (HPA) system is related to severity of benzodiazepine withdrawal in patients with depression. Psychoneuroendocrinology 29 (2004) 1101-1108
56. Verdoux H., and Bourgeois M. [Short-term sequelae of lithium discontinuation]. Encephale 19 (1993) 645-650
57. Steiger A., Benkert O., and Holsboer F. Effects of long-term treatment with the MAO-A inhibitor moclobemide on sleep EEG and nocturnal hormonal secretion in normal men. Neuropsychobiology 30 (1994) 101-105
58. Feige B., Voderholzer U., Riemann D., Dittmann R., Hohagen F., and Berger M. Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects. Neuropsychopharmacology 26 (2002) 246-258
59. D'Aquila P.S., Peana A.T., Panin F., Grixoni C., Cossu M., and Serra G. Reversal of antidepressant-induced dopaminergic behavioural supersensitivity after long-term chronic imipramine withdrawal. Eur J Pharmacol 458 (2003) 129-134
60. D'Aquila P.S., Panin F., and Serra G. Long-term imipramine withdrawal induces a depressive-like behaviour in the forced swimming test. Eur J Pharmacol 492 (2004) 61-63
61. Verster J.C., and Volkerts E.R. Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. CNS Drug Rev 10 (2004) 45-76
62. Lerman C., Niaura R., Collins B.N., et al. Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol Addict Behav 18 (2004) 362-366
63. Wolfe R.M. Antidepressant withdrawal reactions. Am Fam Physician 56 (1997) 455-462
64. Feige B., Voderholzer U., Riemann D., Dittmann R., Hohagen F., and Berger M. Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects. Neuropsychopharmacology 26 (2002) 246-258
65. Wolfe R.M. Antidepressant withdrawal reactions. Am Fam Physician 56 (1997) 455-462
66. Pace-Schott E.F., Gersh T., Silvestri R., Stickgold R., Salzman C., and Hobson J.A. SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects. J Sleep Res 10 (2001) 129-142
67. Gervasoni D., Panconi E., Henninot V., et al. Effect of chronic treatment with milnacipran on sleep architecture in rats compared with paroxetine and imipramine. Pharmacol Biochem Behav 73 (2002) 557-563
68. De Oliveira R.A., Cunha G.M., Borges K.D., et al. The effect of venlafaxine on behaviour, body weight and striatal monoamine levels on sleep-deprived female rats. Pharmacol Biochem Behav 79 (2004) 499-506
69. Stolley P.D. Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 105 (1972) 883-890
70. Aellig W.H. Pindolol-a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations. Br J Clin Pharmacol 13 Suppl 2 (1982) 187S-192S
71. Newcomb R., Tashkin D.P., Hui K.K., Conolly M.E., Lee E., and Dauphinee B. Rebound hyperresponsiveness to muscarinic stimulation after chronic therapy with an inhaled muscarinic antagonist. Am Rev Respir Dis 132 (1985) 12-15
72. Vathenen A.S., Knox A.J., Higgins B.G., Britton J.R., and Tattersfield A.E. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1 (1988) 554-558
73. Svedmyr N. Action of corticosteroids on beta-adrenergic receptors. Clinical aspects. Am Rev Respir Dis 141 2, Part 2 (1990) S31-S38
74. Cochrane G.M. Bronchial asthma and the role of beta 2-agonists. Lung 168 Suppl (1990) 66-70
75. Svedmyr N. The current place of beta 2-agonists in the management of asthma. Lung 168 Suppl (1990) 105-110
76. Mintzer M.J. Asthma therapy: present trends and future prospects. Compr Ther 16 (1990) 12-16
77. Beach R., Young C.L., Harkawat R., et al. Effect on airway responsiveness of six weeks treatment with salmeterol. Pulm Pharmacol 6 (1993) 155-157
78. Yates D.H., Sussman H.S., Shaw M.J., Barnes P.J., and Chung K.F. Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med 152 4, Part 1 (1995) 1170-1174
79. De Jong J.W., van der Mark T.W., Koeter G.H., and Postma D.S. Rebound airway obstruction and responsiveness after cessation of terbutaline: effects of budesonide. Am J Respir Crit Care Med 153 (1996) 70-75
80. Kozlik-Feldmann R., von Berg A., Berdel D., and Reinhardt D. Long-term effects of formoterol and salbutamol on bronchial hyperreactivity and beta-adrenoceptor density on lymphocytes in children with bronchial asthma. Eur J Med Res 1 (1996) 465-470
81. Wilding P.J., Clark M.M., Oborne J., Bennett J.A., and Tattersfield A.E. Effect of regular terbutaline on the airway response to inhaled budesonide. Thorax 51 (1996) 989-992
82. Bennett J.A., Thompson Coon J., Pavord I.D., Wilding P.J., and Tattersfield A.E. The airway effects of stopping regular oral theophylline in patients with asthma. Br J Clin Pharmacol 45 (1998) 402-404
83. Hancox R.J., Cowan J.O., Flannery E.M., Herbison G.P., McLachlan C.R., and Taylor D.R. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment. Respir Med 94 (2000) 767-771
84. Farmer P., and Pugin J. Beta-adrenergic agonists exert their 'anti-inflammatory' effects in monocytic cells through the IkappaB/NF-kappaB pathway. Am J Physiol Lung Cell Mol Physiol 279 (2000) L675-L682
85. Van Schayck C.P., Cloosterman S.G., Bijl-Hofland I.D., Van den Hoogen H., Folgering H.T., and Van Weel C. Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists. Respir Med 96 (2002) 155-162
86. US Food and Drug Administration. FDA Public Health Advisory: 'Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate & salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder)'. Available on: 〈http://www.fda.gov/cder/drug/advisory/LABA.htm〉.
87. a Annual International Scientific Assembly of The American College of Chest Physicians, Orlando, EUA, 2003. CHEST 124 (2003) 335S
88. US Food and Drug Administration. The FDA Safety Information and Adverse Event Reporting Program: 2003 Safety Alert-Serevent (salmeterol xinafoate). Available on: 〈http://www.fda.gov/medwatch/SAFETY/2003/serevent.htm〉.
89. Health Canada. Advisory 2005-107, October 4, 2005: Safety information about a class of asthma drugs known as long-acting beta-2 agonists. Available on: 〈http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/2005/2005_107_e.html〉.
90. Lurie P., and Wolfe S.M. Misleading data analyses in salmeterol (SMART) study. Lancet 366 (2005) 1261-1262 discussion 1262
91. Peper A. A theory of drug tolerance and dependence I: a conceptual analysis. J Theor Biol 229 (2004) 477-490
92. Peper A. A theory of drug tolerance and dependence II: the mathematical model. J Theor Biol 229 (2004) 491-500